From Data to Debate: Global Perspectives on HR+/HER2- mBC

Overview
This online CME activity explores current and emerging strategies for optimizing treatment in hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2- mBC). The discussion highlights pivotal trials of CDK4/6 inhibitors and oral selective estrogen receptor degraders (SERDs), emphasizing their roles in individualized treatment planning and sequencing. Participants gain insight into how biomarker testing and molecular profiling inform therapeutic decision-making and how to adapt these strategies to diverse global healthcare contexts. The program also underscores the importance of early recognition and proactive management of adverse events to sustain treatment adherence and quality of life. Through expert dialogue and case-based debates, this activity provides practical, evidence-based perspectives on advancing HR+/HER2- mBC care worldwide.

*This program is not intended for health care professionals in the United Kingdom.

Update: On May 1, 2026, the FDA approved vepdegestrant for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Efficacy was evaluated in the VERITAC-2 trial.

Update: On September 4, 2026, the FDA granted accelerated approval to camizestrant in combination with a CDK4/6 inhibitor for the treatment of adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK 4/6 inhibitor therapy. Efficacy was evaluated in the SERENA-6 trial.

Update: On September 18, 2026, the FDA approved imlunestrant in combination with abemaciclib for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Efficacy was evaluated in the EMBER-3 trial.
Commercial Support
This activity is supported by an independent educational grant from Eli Lilly and Company.
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, it is the policy of MEDCON International that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. MEDCON International has full policies in place that have identified and mitigated financial relationships and conflicts of interest to ensure independence, objectivity, balance, and scientific accuracy prior to this educational activity.

The following faculty/staff members have reported financial relationships with ineligible companies within the last 24 months.

Chair:
Giuseppe Curgliano, MD, PhD
Director of Early Drug Development Division
Co-Chair Experimental Therapeutics Program
European Institute of Oncology
Mlian, Italy

Advisor/Consultant:Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly and Company, Exact Sciences, Menarini Group, Merck & Co., Novartis, Pfizer, Roche

Cynthia Villarreal-Garza, MD, DSc
Director of Clinical Oncology
Breast Cancer Center
TecSalud Hospitals Nuevo Leon 
San Pedro Garza Garcia, Mexico

Contracted Researcher: AstraZeneca, Gilead Sciences, Pfizer
Advisor/Consultant: AstraZeneca, Eli Lilly, MSD, Novartis

Hiraji Iwata, MD, PhD
Specially Appointed Professor
Nagoya City University
Nagoya, Japan 

Advisor/Consultant: AstraZeneca, Chugai, Daiichi Sankyo, Gilead Sciences, Lilly, MSD

Komal Jhaveri, MD, FACP
Patricia and James Cayne Chair for Junior Faculty
Associate Attending
Memorial Sloan Kettering Cancer Center
New York, NY

Advisor/Consultant: AbbVie, AstraZeneca, Bicycle Therapeutics, Biotheranostics, Blueprint Medicines, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Genentech/Roche, Gilead Sciences, Intellisphere, Jounce Therapeutics, Lilly, Novartis, Pfizer, Sanofi, Scorpion Therapeutics, Seagen, Taiho Pharmaceutical
Research Funding: AstraZeneca, Blueprint Medicines, Context Therapeutics, Genentech, Gilead Sciences, Lilly, Novartis, Pfizer, Puma Biotechnology, RayzeBio, Scorpion Therapeutics, VelosBio/Merck, Zymeworks

Reviewers/Content Planners/Authors: 
- Cindy Davidson has no relevant relationships to disclose. 
- Bing-E Xu, PhD, has no relevant relationships to disclose. 
- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose. 
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Select optimal endocrine therapy backbones in HR+/HER2- metastatic breast cancer (mBC) based on ESR1 mutational status and clinical characteristics
- Evaluate pivotal clinical trial data on CDK4/6 inhibitors and oral selective estrogen receptor degraders to inform evidence-based practice in HR+/HER2- mBC 
- Optimize treatment selection in HR+/HER2- mBC by integrating biomarker insights, clinical characteristics, and emerging therapeutic strategies relevant to global care delivery 
- Apply proactive adverse event monitoring and management strategies to improve adherence to targeted therapies in HR+/HER2- mBC across diverse healthcare settings
Target Audience
This activity has been designed to meet the educational needs of medical oncologists and nurses as well as all other healthcare providers involved in managing patients with HR+/HER2- metastatic breast cancer (mBC). 
Accreditation and Credit Designation Statements
This activity has been accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®). Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association physicians may convert EBAC® CE credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other healthcare professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™. 
This enduring activity is accredited by the European Board for Accreditation of Continuing Education for Health Professional (EBAC®) for 60 minutes of effective education time.
Provider(s)/Educational Partner(s)

Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MEDCON. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information.

Reproduction Prohibited Reproduction of this material is not permitted without written permission from the copyright owner. 
System Requirements
- Supported Browsers (2 most recent versions):
- - Google Chrome for Windows, Mac OS, iOS, and Android
  - Apple Safari for Mac OS and iOS
  - Mozilla Firefox for Windows, Mac OS, iOS, and Android
  - Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 12/02/2025
Expiration Date: 12/02/2026